12:00 AM
 | 
Nov 04, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Antara fenofibrate regulatory update

Lupin said FDA approved an sNDA for 30 and 90 mg strengths of Antara fenofibrate as an adjunct treatment for hypercholesterolemia, mixed dyslipidemia and hypertriglyceridemia in combination...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >